Ainhoa Madariaga, Medical Oncologist at University Hospital October 12, shared an article by Husam A. Alqaisi, et al. on X:
“Rethinking control arms in PlatR ovarian cancer.
Investigator initiated Phase II trial:
Anetumab+Bev vs weekly Taxol +Bev.
Weekly Taxol+ Bev: mPFS 12.7m, ORR 65%.
Role of IL6?”
Randomized phase II study of bevacizumab with weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant/refractory high grade ovarian cancer (NCI trial).
Authors: Husam A. Alqaisi, et al.
